A Phase 2/3 interventional study of SPM 962 in Parkinson's Disease, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 7 sites in Japan. Per ClinicalTrials.gov, last updated 2014-03-19.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.
Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 18th largest by enrollment of the 42 interventional ones that give a count, is the only one that started in 2008, is one of 2 in phase 2/3, and was the 25th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:
Eva Pharma
Ages 30+
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 22 · Phase 4 8
First in 1999; this study’s year is marked. 1 started in 2008.
This study's enrollment of 143 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 123 across the 42 interventional studies. Of the 41 that completed or were terminated, 30 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
12 studies in Parkinson Disease by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 12 finished, 9 (75%) have results posted.
Among the 12 studies in Parkinson Disease by Otsuka Holdings Co., Ltd., this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2008, is one of 2 in phase 2/3, and was the 7th registered.
Otsuka Holdings Co., Ltd.’s Parkinson Disease studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing rotigotine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 12 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Safety of SPM 962 in a once-daily repeated long-term treatment in Parkinson's disease patients who are not concomitantly treated with L-dopa will be investigated with a doses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SPM 962 transdermal patch
Drug: SPM 962
SPM 962 transdermal patch once a daily up to 36.0 mg/day
Also known as: rotigotine
Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters
Incidence and severity of adverse events, vital signs, and laboratory parameters up to 54 weeks after dosing. \*decrease in difference between supine and standing systolic blood pressure
Time frame: Up to 55 weeks after dosing
Skin Irritation Score of the Application Site
Skin irritation score of the application site were evaluated according to the criteria below. The worst score throughout the treatment period was used in the analysis. -: no reaction, ±: mild erythema, +: erythema, ++: erythema and Oedema, +++: erythema and oedema and rash papular, or serous papule, or vesicles, ++++: bullosum
Time frame: Up to 55 weeks after dosing
Total of Unified Parkinson's Disease Rating Scale (UPDRS) Part 2 Sum Score and Part 3 Sum Score
Mean change (LOCF) from baseline in Total of UPDRS Part 2 sum score and Part 3 sum up to 54 weeks after dosingUPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Time frame: Baseline, Up to 54 weeks after dosing
| Milestone | SPM 962 |
|---|---|
| Started | 143 |
| Completed | 94 |
| Not completed | 49 |
| Withdrew: Adverse event | 30 |
| Withdrew: Lack of efficacy | 7 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Discontinuation criteria | 8 |
Incidence and severity of adverse events, vital signs, and laboratory parameters up to 54 weeks after dosing. \*decrease in difference between supine and standing systolic blood pressure
| participants | SPM 962 |
|---|---|
| Any AEs | 140 |
| Treatment-related AEs | 122 |
| SAEs | 18 |
| Severe AEs | 9 |
| Discontinuation due to AEs | 30 |
| Severe laboratory abnormality | 14 |
| ≥30 mmHg decrease* | 1 |
| Treatment-related AE of orthostatic hypotension | 2 |
| QTcB ≥500 ms | 1 |
| Weight decrease of 5% or more | 53 |
| Weight increase of 5% or more | 22 |
Mean change (LOCF) from baseline in Total of UPDRS Part 2 sum score and Part 3 sum up to 54 weeks after dosingUPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
| Scores on a scale | SPM 962 |
|---|---|
| Week 12 | -9.9 ± 8.7 |
| Week 24 | -8.3 ± 9.5 |
| Week 52 | -6.5 ± 10.1 |
Skin irritation score of the application site were evaluated according to the criteria below. The worst score throughout the treatment period was used in the analysis. -: no reaction, ±: mild erythema, +: erythema, ++: erythema and Oedema, +++: erythema and oedema and rash papular, or serous papule, or vesicles, ++++: bullosum
| participants | SPM 962 |
|---|---|
| - | 20 |
| ± | 57 |
| + | 46 |
| ++ | 12 |
| +++ | 6 |
| ++++ | 1 |
| +++> | 7 |
Collected over 54 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SPM 962 | — | 24/143 (16.8%) | 138/143 (96.5%) |
| Event | SPM 962 |
|---|---|
| Spinal Compression FractureInjury, poisoning and procedural complications | 2/143 |
| DehydrationMetabolism and nutrition disorders | 2/143 |
| Positional VertigoEar and labyrinth disorders | 1/143 |
| CataractEye disorders | 1/143 |
| Gastric Ulcer BleedingGastrointestinal disorders | 1/143 |
| PyrexiaGeneral disorders | 1/143 |
| Gallbladder PolypHepatobiliary disorders | 1/143 |
| PyelonephritisInfections and infestations | 1/143 |
| Clavicle FractureInjury, poisoning and procedural complications | 1/143 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/143 |
| Event | SPM 962 |
|---|---|
| Application Site ReactionGeneral disorders | 96/143 |
| NauseaGastrointestinal disorders | 47/143 |
| NasopharyngitisInfections and infestations | 26/143 |
| VomitingGastrointestinal disorders | 22/143 |
| ConstipationGastrointestinal disorders | 21/143 |
| SomnolencePsychiatric disorders | 17/143 |
| Back PainMusculoskeletal and connective tissue disorders | 13/143 |
| InsomniaPsychiatric disorders | 10/143 |
| DizzinessNervous system disorders | 8/143 |
| Oedema PeripheralGeneral disorders | 7/143 |
| Age, Categorical(Participants) | SPM 962 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 58 |
| >=65 years | 85 |
| Age, Continuous(years) | SPM 962 |
|---|---|
| Mean | 65.3 ± 8.4 |
| Sex: Female, Male(Participants) | SPM 962 |
|---|---|
| Female | 83 |
| Male | 60 |
| Region of Enrollment(participants) | SPM 962 |
|---|---|
| Japan | 143 |
The record gives a start of Jan 2008, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine
Otsuka Pharmaceutical Co., Ltd. →